Vitamin D Interactions

Phenobarbital activates the pregnane X receptor and constitutive androstane receptor, strongly inducing hepatic CYP3A4 while also directly suppressing CYP27A1 (a 25-hydroxylase), so it both accelerates breakdown of 25-hydroxyvitamin D and slows its formation; serum 25(OH)D drops substantially over weeks to months of therapy, with osteomalacia and increased fracture risk documented in long-term users.

Phenytoin induces hepatic CYP3A4 and CYP24A1, accelerating conversion of 25-hydroxyvitamin D to inactive metabolites and lowering circulating 25(OH)D, which over time produces secondary hyperparathyroidism, reduced calcium absorption, and a measurably increased risk of osteomalacia and fractures.

Carbamazepine activates the pregnane X receptor and strongly induces hepatic CYP3A4 and CYP24A1, accelerating catabolism of 25-hydroxyvitamin D into inactive metabolites; meta-analyses confirm consistently lower 25(OH)D in long-term users along with secondary hyperparathyroidism and reduced bone mineral density.

Glucocorticoids accelerate the catabolism of 25-hydroxyvitamin D, lower active vitamin D metabolites at the gut, and impair calcium absorption. Population data show oral steroid users have more than double the rate of severe vitamin D deficiency compared to non-users.

Methylprednisolone, like other glucocorticoids, is associated with increased catabolism of 25-hydroxyvitamin D and impaired vitamin D-mediated intestinal calcium absorption. Long-term use contributes to vitamin D deficiency and accelerated bone loss.

Vitamin D's active metabolite (calcitriol) can induce CYP3A4, which metabolizes atorvastatin. Small studies show vitamin D supplementation may reduce atorvastatin and metabolite plasma levels by up to ~55%, although LDL-lowering efficacy appears largely preserved.

In vitro and observational studies suggest high caffeine intake (>300 mg/day) may decrease vitamin D receptor (VDR) protein expression in osteoblasts and is associated with lower serum 25-hydroxyvitamin D levels in some NHANES data. The clinical effect is modest and most relevant for bone health in postmenopausal women with low calcium intake.

Vitamin D supplementation does not chemically interfere with the parathyroid hormone (PTH) assay itself, but it physiologically suppresses PTH secretion by raising serum 25-hydroxyvitamin D and calcium levels. A PTH drawn after starting or adjusting vitamin D can therefore look lower than the patient's true baseline, complicating workup of suspected primary hyperparathyroidism or vitamin D deficiency.

Fat from omega-3 improves fat-soluble vitamin D absorption

Magnesium is needed to convert vitamin D into its active form

Vitamin K2 helps direct calcium (mobilized by vitamin D) into bones, not arteries

Vitamins A and D share the same nuclear receptor partner, RXR, and work together to regulate gene transcription affecting immunity, bone metabolism, and epithelial health. Moderate intake of both supports balanced signaling, though very high doses of one can blunt the action of the other.

Vitamin D and probiotics share regulatory pathways: vitamin D supports VDR expression in gut epithelium, which probiotics depend on for anti-inflammatory and barrier effects, while certain probiotic strains modestly raise serum 25(OH)D. Combined supplementation outperforms either alone for inflammatory and gut-barrier endpoints in randomized trials.